Key Highlights:
- Wockhardt’s novel antibacterial candidate Zaynich has received a favorable recommendation for marketing approval from the Subject Expert Committee (SEC) under Central Drugs Standard Control Organization, paving the way for final approval in India
- The recommendation is backed by a comprehensive clinical package, including nine Phase 1 studies, a multi-indication Phase 2 study in meropenem-resistant infections, a global Phase 3 study in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), along with data from 85 compassionate-use cases
- Zaynich, a dual-mechanism antibiotic targeting MDR and XDR pathogens, has demonstrated >97% clinical efficacy in real-world studies in India and has received QIDP and Fast Track Designation from the US FDA, with further regulatory milestones expected across the US and EU in 2026
Implications:
Wockhardt’s SEC nod for Zaynich marks a major step toward India’s first home-grown, dual‑mechanism anti‑Gram‑negative launched in the carbapenem‑resistant era, positioning it as a potential go‑to option for MDR/XDR cUTI, AP, and serious hospital infections where meropenem is failing.
With nine Phase 1 trials, a Phase 2 in meropenem‑resistant infections, a global Phase 3 that outperformed meropenem in cUTI/AP, and >97% clinical efficacy plus strong outcomes in 85 compassionate‑use XDR cases, Zaynich arrives with an unusually deep evidence package for an Indian-origin antibiotic and is further de‑risked by QIDP and Fast Track status as Wockhardt pursues US and EU approvals in 2026.
Source: Wockhardt I Image: Wockhardt
